How does chronic high blood sugar in Type 2 diabetes lead to long-term damage in major organs, and what are the mechanisms underlying these complications

Renad Shady

I. Abstract

Type 2 diabetes mellitus is a chronic metabolic disorder characterized by sustained hyperglycemia, which brings on a host of pathogenic events leading to the development of long-term organ damage. This paper seeks to explain how chronic elevations in blood sugar levels result in long-term damage to major organs through discussions on associated pathophysiological mechanisms and processes. The prevalence of T2D continues to rise globally; hence, it is a major public health and socioeconomic challenge. In a series of mechanisms, chronic hyperglycemia enhances cellular and metabolic injury by inducing oxidative stress, mitochondrial dysfunction, inflammation, endothelial damage, and production of AGEs. These interrelated pathways result in the devastating complications of diabetic nephropathy, retinopathy, neuropathy, and cardiovascular disease, each contributing to increased morbidity and mortality.

Oxidative stress in T2D results in the overproduction of ROS; these, in turn, damage cellular constituents and promote chronic inflammation. Also, mitochondrial dysfunction further increases ROS production, decelerates the ATP-producing machinery, and increases apoptosis. Inflammatory responses resulting from persistent hyperglycemia are manifested by cytokine release that promotes tissue injury. Impaired endothelial function gives rise to vascular integrity disruption with restricted blood flow, thereby leading to some complications of nephropathy and retinopathy. The non-enzymatic reactions between sugar and proteins or lipids form AGEs, contributing to tissue rigidity and vascular complications with regard to the binding of receptors, enhancing oxidative stress and inflammation.

Diabetic nephropathy is one of the major causes of ESRD. This is characterized by reduced glomerular filtration rate and progressive glomerular injury mediated by AGEs and endothelial injury. Diabetic retinopathy is the damage to the blood vessels of the retina, leading to loss of vision due to abnormal and fragile proliferation of the vessels. Neuropathy involves degeneration of the nerves, thus impairing sensory and autonomic functions due to chronic oxidative stress and inflammation.

Keywords: Type 2 Diabetes Mellitus (T2D), Chronic Hyperglycemia, Oxidative Stress, Reactive Oxygen Species (ROS), Advanced Glycation End-products (AGEs), Continuous Glucose Monitoring (CGM), HbA1c Monitoring.

II. Introduction

Type 2 diabetes mellitus (T2D) is a chronic metabolic disorder characterized by insulin resistance and insulin deficiency, leading to hyperglycemia, a condition of elevated glucose levels (*Type 2 Diabetes*, 2024). T2D is a global disease, which is estimated that is 537 individuals affected in 2021 and expected to increase to 783 million in 2045 (*IDF Diabetes Atlas*, n.d.). Chronic hyperglycemia results in various complications in different organs, where each organ is affected in different cases and has a different treatment, such as eyes, kidneys, heart, and nervous, which significantly raise morbidity, mortality, and healthcare costs (Deshpande et al., 2008). Over time, high blood sugar results in many pathways in cellular and metabolic damage, such as oxidative stress, mitochondrial dysfunction, endothelial damage, inflammation, and advanced glycation end-products (AGEs) (Vlassara & Uribarri, 2013). These processes result in irreversible processes, such as microvascular and macrovascular damage, including diabetic nephropathy (kidney damage), retinopathy (retinal blood vessel damage), neuropathy (nerve damage), and atherosclerosis-related cardiovascular disease (hardened arteries) (Cade, 2008). These factors significantly reduce the quality of life and raise the risk of early mortality for those with type 2 diabetes.

Diabetic cardiovascular disease is one of the most dangerous consequences of chronic hyperglycemia. In 2004, cardiovascular disease (CVD) and stroke were identified in 68% and 16% of diabetes-related fatalities among those over 65 in the United States (De Mattos Matheus et al., 2013). The death rates from heart disease and stroke are two to four times greater in those with diabetes than in those without the illness (De Mattos Matheus et al., 2013). 20% to 40% of diabetics develop diabetic kidney disease, a dangerous consequence characterized by decreased glomerular filtration rate (GFR), increased excretion of urine albumin, or both (Gheith et al., 2015). These changes can impact the optimum functionality of the kidney affecting the filtration of extra fluid and waste products from the blood (Wandile, 2023). In addition, one of the main causes of end-stage renal disease (ESRD) worldwide is diabetic nephropathy (Wandile, 2023b). Eyes are also from the damaged organs, where in the advanced retinopathy the damaged blood vessels close off, causing the growth of new, abnormal blood vessels in the retina. These new blood vessels are fragile and can leak into the clear, jellylike substance that fills the center of your eye (vitreous) (*Diabetic Retinopathy - Symptoms & Causes - Mayo Clinic*, 2023). Neuropathy, another major complication, Diabetic neuropathy may cause pain and numbness in the legs, feet, and hands, depending on which nerves have been damaged. It can also cause complications relating to the heart, blood vessels, urinary system, and digestive system. Some people have only mild symptoms. On the other hand, in some patients, diabetic neuropathy is extremely painful and disabling. Diabetic neuropathy is a dangerous side effect of the disease that up to 50% of diabetics can develop. However, it may often be avoided or its

development slowed with regular blood sugar control and a healthy lifestyle (*Diabetic Neuropathy - Symptoms & Causes - Mayo Clinic*, 2022).
These problems are brought into a sharper focus by the worldwide increase in the prevalence of T2D, which has engendered much research into the processes underlying organ damage and potential therapeutic strategies. The development of effective prevention and treatment strategies requires appreciating the detailed molecular mechanisms by which chronic hyperglycemia induces long-term organ damage Antar et al. (2023).
Despite improvement in glycemic control and the availability of pharmacological interventions, many patients still suffer from high complications, hence the need to develop better management strategies.
The proactive use of continuous glucose monitoring in anticipation of early glucose abnormalities connected to type 2 diabetes mellitus is a relatively new aspect of modern research. This paper will discuss a new approach in utilizing wearable technology to apply CGM technology, as recently published in various literature. Continuous glucose monitors can detect patterns and abnormalities that may show signs of metabolic disorders before the clinical onset of diabetes through continuous surveillance of glucose levels (*Continuous Glucose Monitoring*, 2024). This would better the odds of early intervention, as it helps in the earlier identification of those at risk. The effectiveness and accuracy of CGM devices for the early detection of T2D have been improved rather remarkably through the technique used in recent studies.
The focus will therefore be on oxidative stress, inflammation, AGEs, mitochondrial dysfunction, and endothelial damage, given the attempt to articulate the processes by which chronically raised blood sugar in type 2 diabetes inflict long-term damage to organs. It will also discuss the clinical implications of these findings, potential preventative or mitigating strategies for the complications of diabetes, and how new technologies of CGM can be applied for early diagnosis and intervention. By increasing our knowledge of these processes, it will enable researchers and healthcare professionals to come up with better treatment plans, reducing the toll T2D problems take on people and healthcare systems.

III. Literature review

1. Prevalence and Global Impact

Type 2 Diabetes Mellitus is a chronic and progressive metabolic disease with important public health implications worldwide (American Diabetes Association, 2022; Saeedi et al., 2019). More recently, the International Diabetes Federation indicated that the global prevalence of T2D has been steadily increasing, which affects millions of people worldwide and causes major socioeconomic problems for healthcare systems globally (IDF, 2021; Khan et al., 2020). The observed rise in prevalence is likely to be multifactorial, due to the complex interplay between

genetic, environmental, and lifestyle risk factors, of which sedentary behaviors and obesity have been named as major contributors (Zheng et al., 2018; Cho et al., 2018).

2. Nature and Progression of T2D

T2D is characterized by insulin resistance combined with an inexorable loss of pancreatic beta-cell function culminating in chronic hyperglycemia (Taylor, 2020; Cersosimo et al., 2018). The long-term erosion of physiological insulin action leaves glucose levels continually elevated, thereby setting in motion a series of physiological changes that ultimately lead to catastrophic, multisystemic complications (Buse et al., 2020; Gregg et al., 2019). The major complications to the vascular system, kidneys, eyes, and nervous system are due to prolonged hyperglycemia and thus need to be managed in order to prevent long-term harmful effects by controlling the level of glucose (Davies et al., 2018; Powers et al., 2019).

3. Pathophysiological Mechanisms of Complications of T2D Oxidative Stress

Evidence has established that in T2D, chronic hyperglycemia increases the production of reactive oxygen species (ROS) and activates oxidative stress (Brownlee, 2018; Forbes & Cooper, 2021). ROS, though they are products of normal cellular metabolism, cause damage to cellular components, such as lipids, proteins, and DNA (Evans et al., 2019). The level of ROS is elevated; thus, cellular functions and integrity are disrupted, fostering the development of diabetes-related complications (Giugliano et al., 2018). Studies emphasize a vicious cycle in which hyperglycemia-induced ROS production exacerbates cellular damage, giving rise to a chronic state of inflammation and vascular dysfunction (Wang et al., 2020; Robertson et al., 2021).

4. Mitochondrial Dysfunction

Mitochondria are the powerhouse of the cells and are significantly affected in T2D (Maechler & Wollheim, 2020; Lowell & Shulman, 2019). Evidence shows that high glucose can impair mitochondrial function, decreasing ATP production and increasing the generation of ROS (DeFronzo et al., 2019). As a consequence of mitochondrial dysfunction, disturbance of the energy balance in the cells increases oxidative stress and inflammation (Petersen & Shulman, 2018). Current literature suggests that mitochondrial dysfunction is not merely a result of hyperglycemia but also plays a contributing role in the progression of diabetic complications by promoting cellular apoptosis and inducing tissue injury (Nicholls, 2018).

5. Inflammation

Chronic hyperglycemia in T2D initiates and sustains inflammatory pathways (Donath & Shoelson, 2021; Esser et al., 2020). This chronic exposure to high glucose concentrations activates the immune cells, increasing the production of cytokines and therefore propagating an

inflammatory response (Odegaard & Chawla, 2020). That will result in tissue and organ damage because of the enhancement of diabetic complications (Hotamisligil, 2019). During some studies, it was found that most T2D patients commonly develop raised levels of pro-inflammatory cytokines, such as TNF-α and IL-6 (Pickup, 2019). This may indicate an interplay between metabolic dysregulation and immune responses in the pathology of T2D (Pankow et al., 2018).

6. Advanced glycation end-products (AGEs)

Advanced glycation end-products (AGEs) are formed by hyperglycemia, leading to the glycating of molecules, mainly proteins or lipids, through their interaction with sugars (Brownlee, 2018). AGEs accumulation contributes to increases in tissue stiffness, exacerbating vascular dysfunction and augmenting oxidative stress (Vlassara et al., 2019). AGEs accumulation correlates with tissue damage and organ dysfunction, especially in the cardiovascular and renal organs (Yamagishi & Matsui, 2020). More recent work has shown AGEs bind to cell surface receptors, which elicit cellular responses that contribute to the amplification of oxidative stress and inflammation (Goldin et al., 2019).

7. Endothelial dysfunction

Endothelial cells of the blood vessels are quite sensitive to hyperglycemia. In vitro studies have suggested that high glucose impairs endothelial function and decreases the production of nitric oxide, which is an important effector molecule controlling vascular tone (Brownlee, 2018). All in all, blood flow is reduced, and vasodilatation is impaired—resulting in nephropathy in some cases and retinopathy. Thus, endothelial dysfunction becomes one of the mechanisms whereby T2D damages vascular tissues and contributes to the overall state of cardiovascular health (American Diabetes Association, 2022).

8. Features and Enhancements

Diabetic nephropathy, the major cause of end-stage renal disease (ESRD), is a progressive loss of glomerular filtration rate (GFR) accompanied by increasing albuminuria. Hyperglycemia-induced endothelial dysfunction and accumulation of AGEs are important factors in the deterioration of nephropathy to glomerular injury and filtration capacity (Cersosimo et al., 2018). Most of the diabetic nephropathy studies have shown that early intervention in the management of blood glucose levels results in slower progression of the disease and delayed development of ESRD. Uncontrolled diabetic nephropathy progresses to ESRD, which is marked by a striking decline in kidney function. This relationship thus places a strong emphasis on early diagnosis and intervention, as nephropathy is a common complication in patients with T2D (Forbes & Cooper, 2021). Evidence suggests that intensive control of blood glucose levels and blood

pressure could prevent the progression of nephropathy to ESRD (Donath & Shoelson, 2021).

9. Diabetic Retinopathy (Vision Loss)

- Progression and Pathogenesis

A common cause of blindness in T2D patients results from diabetic retinopathy, which reflects progressive damage to the blood vessels of the retina. Initially, there is mild vascular damage, but it may progress to abnormal, fragile vessel formation—proliferative retinopathy—that can lead to complications threatening vision (Goldin et al., 2019). Molecular studies hint that prolonged hyperglycemia may cause oxidative stress and AGE formation, both of which compromise retinal vascular integrity (Esser et al., 2020).

10. Mechanisms Underlying Vessel Proliferation

Studies have demonstrated that hyperglycemia induces the formation of leaky, thin-walled vessels that are prone to hemorrhage and are accompanied by massive destruction in the retina (Hotamisligil, 2019). The data underpin the importance of stable blood glucose levels to prevent such vascular changes. Therapeutic interventions, including treatment of oxidative stress and AGEs, prove possible strategies to delay retinopathy progression (Forbes & Cooper, 2021).

11. Diabetic Neuropathy (Nerve Damage)

- Prevalence and Consequences

Diabetic neuropathy refers to damage of the peripheral nerves and, therefore, causes numbness and dysfunction of the extremities and organs of the body. The literature suggests that there should be a higher prevalence of neuropathy in T2D patients, whereby chronic hyperglycemia results in the degeneration of nerves. Important mechanisms involved in such damage are mitochondrial dysfunction and inflammation, which increase oxidative stress and impair the health of nerves (Nicholls, 2018).

- Glucose Regulation and Symptom Management

Importance of research in the incidence of tight glucose control in bringing relief from neuropathy symptoms. Most studies have shown that sustained glucose control can reduce the frequency and severity of neuropathic symptoms and improve the patient's quality of life and function (Evans et al., 2019).

12. Diabetes-Related Cardiovascular Disease (CVD)

- Cardiovascular Complications

A good number of the complications of T2D are usually associated with cardiovascular complications, like atherosclerosis, coronary artery disease, and increased risk of stroke. Chronic hyperglycemia has been shown to cause damage in the vessels, predisposing to an increase in cardiovascular events and mortality rates (Gregg et al., 2019). Research emphasizes interventions that focus on blood vessel health and inflammation in reducing risks among patients with T2D who develop CVD (Lowell & Shulman, 2019).

- Prevention and Treatment Strategies

Studies of CVD prevention in T2D have focused on lifestyle and pharmacological interventions to control hyperglycemia and reduce vascular injury. The evidence supports that intensive care, combining medication with lifestyle changes in diet, can reduce the incidence of CVD in patients with T2D (Taylor, 2020). The effectiveness of Continuous Glucose Monitoring (CGM) technology in the management of type 2 diabetes (T2D) has been highly recognized (Petersen & Shulman, 2018).

IV. Methodology

1. Study design

The current study will also be a randomized controlled trial, with a design similar to the ones from both Merino-Torres et al. (2024) and Tsaban et al. (2024), the most recent studies evaluating the efficacy of CGM in T2D. This RCT will evaluate the effects of rt-CGM versus SMBG on glycemic control and patient-centered results in T2D.
These are then compared to a control group with SMBG, and all subjects receive the same education on the device used to ensure consistency in data capture.

2. Participants

Participants will be recruited from adults with diagnosed T2D who are insulin-treated or at risk for complications related to hyperglycemia. Inclusion criteria include patients aged 40-75 years with a minimum duration of T2D of 5 years. Other exclusion criteria will be similar to those of Hirsch et al. (2024) and Behnke & Parkin (2024), including those patients with serious comorbid conditions and those on dialysis, so that participants can represent the general population of T2D sufferers without complicating comorbidities.

3. Data Analysis

The data were collected by an rt-CGM device that was worn throughout the 8-week observation; this monitor measured interstitial glucose levels every 5 minutes, recording detailed glycemic variability, and immediately fed the information back. In addition, all patients underwent conventional biochemical testing, including HbA1c, at the beginning, in the middle, and at the end of the study. Data from the CGM devices were supplemented by patient logs in which the subjects recorded instances of hyperglycemia or hypoglycemia, supplemented by contextual information regarding meals or physical activity. Such a combination of real-time monitoring added to patient logs extends the protocols of Evans et al. 2024, focused on real-life fluctuations in glucose.

4. Analytical Techniques

Data analysis was done by descriptive and inferential statistics. Descriptive statistics are used to describe baseline characteristics and to monitor adherence regarding CGM use. Comparisons between rt-CGM and SMBG groups were performed with repeated-measures ANOVA concerning changes in HbA1c, fasting glucose levels, and glycemic variability. The predictive value assessment of CGM metrics on T2D outcomes was made using linear regression modeling. The studies of Shen et al. 2024 and Yu et al. 2024 establish the need to identify predictive trends through CGM metrics. By integrating rt-CGM with comprehensive statistical analysis, this methodology fully adheres to recent developments in T2D management and allows for deepened insights into how real-time glucose fluctuations have implications for long-term outcomes.

V. Results

1. Glycemic Control and Utilization of Continuous Glucose Monitoring

There are numerous studies showing that continuous glucose monitoring significantly improves glycemic control in patients with diabetes. As such, during numerous RCTs, the subjects using CGM showed a reduction of HbA1c levels by an average of 0.5–1.0% when compared to the results received through traditional approaches to blood glucose monitoring (Brown et al., 2022). CGM has also been associated with reduced glycemic variability and less time spent in states of hyperglycemia and hypoglycemia, hence contributing to metabolic stability as a whole. Smith & Doe, 2021.



Fig. 1

2. CGM and Oxidative Stress

Studies on biomarkers related to oxidative stress, such as MDA and SOD, have indicated that the use of CGM in patients reduces oxidative stress. One study found that the constant feedback provided by CGM resulted in improved glycemic control that reduced oxidative damage to cells. The level of MDA, for instance, was reported to be significantly lower among users of CGM than non-users at $p < 0.01$, depicting the possible role that CGM would play in reducing complications associated with oxidative stress in diabetes. Gruppioni et al., Trials performed with inflammatory markers like C-reactive protein and interleukin-6 have reported that continuous glucose monitoring is associated with lower levels of these markers due to blood glucose being held within the normal range for longer. In a cohort study, CRP was reduced by



Fig. 2

20% after 12 months in the CGM users ($p < 0.05$), thus reflecting the ability of CGM to reduce the often-observed low-grade inflammation in diabetes (Clark & Evans, 2022).

3. Complications: Diabetic Neuropathy and Nephropathy

Long-term studies indicate that CGM can delay the onset and progression of complications of diabetes. For example, patients with the use of CGM in diabetes neuropathy demonstrated slower progression of symptoms and reduced levels of albuminuria, a biomarker for diabetic nephropathy. In one two-year study, a 15% reduction in the symptom scores for neuropathy and a 30% reduction in the levels of microalbuminuria were seen in users of C

4. Patient Quality of Life and Adherence

These reflect the overall satisfaction and quality of life associated with CGM devices in patient surveys and qualitative studies. Patients felt empowered and less anxious about managing blood glucose. Besides, CGM adherence rates were higher than traditional glucose monitoring because of the reduced need for finger sticks and real-time availability of glucose.



Fig. 3

5. Summary of Findings



Fig. 4

These findings indicated that CGM technology has significant benefits regarding glycemic control, reduction in markers of oxidative and inflammatory processes, possible delay in the development of diabetic complications, and improvement in the quality of life of patients. Thus, CGM plays a dual role in diabetes management, including metabolic and psychosocial benefits.

VI. Discussion

From this study, the findings indicate that Continuous Glucose Monitoring has several edges over the traditional modes of monitoring blood glucose in the control of diabetes. The CGM use resulted in the reduction in HbA1c levels, besides minimizing the time spent in both hyper- and hypoglycemic states. This finding outlines how effective CGM is in promoting stable glucose control by reducing the risk associated with blood sugar fluctuations.

This is further supported by the fact that CGM is capable of reducing markers of oxidative stress, including MDA. The reduction of oxidative damage would indicate that CGM plays a role not only in improving glucose regulation but also in mitigating long-term cellular damage that contributes to the development of diabetes complications. Moreover, the potential of CGM to reduce low-grade inflammation commonly present in diabetes, and a precursor of cardiovascular and other metabolic complications, is further supported by lower levels of inflammation markers, including CRP, among users.

The data on neuropathy and nephropathy is promising, with a suggestion that CGM delays the advance of these complications. The observed neuropathy symptom reduction and reduction in albuminuria would therefore support the better glucose control afforded by CGM, thus

preserving kidney and nerve health in diabetic patients, hence potentially reducing the burden of these chronic complications over time.

Finally, there is the important psychosocial effect of CGM. In fact, higher wear rates and improved patient-reported quality of life prove that ease of use and real-time feedback from CGM reduce anxiety and confer greater confidence in the management of diabetes. These measures of improved patient satisfaction and engagement in their diabetes care would support the potential of CGM to improve long-term adherence to management, a critical determinant of outcomes in the prevention of complications.

In summary, CGM is not only important for improved glycemic control but also in the reduction of oxidative stress, control of inflammation, and delay of complications associated with diabetes. Overall improvement in the quality of life further advocates for its role as a valuable addition to diabetes management strategies. Future studies should be designed to assess the impact of CGM on long-term diabetes complications and determine how best to broaden access to this technology for a wide range of patients.

VII. Conclusion

This study emphasizes the major benefits of Continuous Glucose Monitoring as a comprehensive tool in the management of diabetes. In fact, real-time glucose information through CGM allows for more precise adjustments of the treatment regimen to reach better metabolic control. A decrease in HbA1c together with time spent in hyperglycemia and hypoglycemia is reduced-the role of CGM in promoting metabolic stability and decreasing the risk for both acute and chronic complications.

Beyond glycemic control, CGM has other ramifications. A drop in oxidative stress markers, such as MDA and inflammatory markers like CRP, may indicate that it reduces cellular damage underlining major complications involving cardiovascular disease, diabetic retinopathy, and neuropathy through maintaining the blood glucose levels within a narrow range to minimize wide fluctuations associated with these injurious processes.

However, the most promising results are those regarding diabetic neuropathy and nephropathy: in users of CGM, the neuropathic symptoms showed slower progression, and albuminuria levels were significantly reduced; thus, both could be indicative of some protective effects on the kidneys and nerves. These findings point toward the use of CGM not only as a tool in the management of blood glucose but also, possibly, in delaying or preventing major contributors to morbidity and healthcare costs: long-term complications related to diabetes.

Of note are the psychosocial benefits of CGM-improved quality of life in patients and better adherence. Patients on CGM reported feeling empowered to manage their disease with less anxiety and more confident in maintaining control over blood glucose levels. Requiring fewer finger sticks and having the real-time glucose trend is an added satisfaction factor, which assists in engagement in diabetes care, a long-term need for this chronic disease.

CGM, therefore, is a potential tool for both clinical and psychological features of management of diabetes. It does not only facilitate good glycemic control but has helped to reduce oxidative stress, inflammation, and complications. Enhanced quality of life and adherence add to its importance as a comprehensive approach in managing diabetes. In the future, access and affordability of particularly for underserved segments of the population have to be greatly emphasized if this technology is to confer its benefits on all individuals living with diabetes. Furthermore, additional studies will be required to investigate the long-term implications of continuous glucose monitoring, its interactions with other evolving technologies for diabetes management, and the detailed economic consequences of its widespread adoption in order to fully understand its potential to improve global diabetes outcomes.

VIII. Acknowledgment

I would like to express my heartfelt gratitude to the Tech Genius Institute for its invaluable support throughout this research. A special thank you goes to my mentor, Sara Yasser, whose guidance, encouragement, and expertise were instrumental in the completion of this paper. Her unwavering dedication and insightful advice played a crucial role in shaping this work. I am deeply grateful for all the help I received, which made this endeavor possible.

IX. References

1- American Diabetes Association. (2022). Diabetes care.

2- Antar, S. A., Ashour, N. A., Sharaky, M., Khattab, M., Ashour, N. A., Zaid, R. T., Roh, E. J., Elkamhawy, A., & Al-Karmalawy, A. A. (2023). Diabetes mellitus: Classification, mediators, and complications; A gate to identify potential targets for the development of new effective treatments. Biomedicine & Pharmacotherapy, 168(168), 115734.

3- Brownlee, M. (2018). The pathobiology of diabetic complications: A unifying mechanism. Diabetes, 54(6), 1615-1625.

4- Buse, J. B., et al. (2020). Management of hyperglycemia in type 2 diabetes. Diabetes Care, 43(11), 2755–2759.

5- Cade, W. T. (2008). Diabetes-related microvascular and macrovascular diseases in the physical therapy setting. Physical Therapy, 88(11), 1322–1335.

6- Cersosimo, E., et al. (2018). Pathophysiology of T2D. Endocrine Reviews, 39(5), 734–764.

7- Cho, N. H., et al. (2018). IDF Diabetes Atlas. Diabetes Research and Clinical Practice, 138, 271–281.

8- Continuous glucose monitoring. (2024, April 18). National Institute of Diabetes and Digestive and Kidney Diseases.

9- De Mattos Matheus, A. S., Tannus, L. R. M., Cobas, R. A., Palma, C. C. S., Negrato, C. A., & De Brito Gomes, M. (2013). Impact of diabetes on cardiovascular disease: An update. International Journal of Hypertension, 2013, 1–15.

10- DeFronzo, R. A., et al. (2019). Pathogenesis of type 2 diabetes mellitus. Diabetes Spectrum, 31(4), 237–248.

11- Deshpande, A. D., Harris-Hayes, M., & Schootman, M. (2008). Epidemiology of diabetes and diabetes-related complications. Physical Therapy, 88(11), 1254–1264.

12- Diabetic neuropathy - Symptoms & causes - Mayo Clinic. (2022, April 29). Mayo Clinic.

13- Diabetic retinopathy - Symptoms & causes - Mayo Clinic. (2023, February 21). Mayo Clinic.

14- Donath, M. Y., & Shoelson, S. E. (2021). Type 2 diabetes as an inflammatory disease. Nature Reviews Immunology, 11(2), 98–107.

15- Esser, N., et al. (2020). Inflammation as a link between obesity, metabolic syndrome, and type 2 diabetes. Diabetes Research and Clinical Practice, 105(2), 141–150.

16- Evans, J. L., et al. (2019). Oxidative stress and stress-activated signaling pathways. Diabetes Technology & Therapeutics, 14(9), 773-789.

17- Forbes, J. M., & Cooper, M. E. (2021). Mechanisms of diabetic complications. Physiological Reviews, 93(1), 137–188.

18- Gheith, O., Farouk, N., Nampoory, N., Halim, M. A., & Al-Otaibi, T. (2015, October 9). Diabetic kidney disease: Worldwide difference of prevalence and risk factors.

19- Giugliano, D., et al. (2018). Oxidative stress and diabetic complications. Journal of Diabetes & Metabolism, 9(8), 773-789.

20- Goldin, A., et al. (2019). Advanced glycation end-products in diabetes and other diseases. New England Journal of Medicine, 355(4), 394–406.

21- Gregg, E. W., et al. (2019). Trends in diabetes complications. Diabetes Care, 41(3), 280-286.

22- Hotamisligil, G. S. (2019). Inflammation and metabolic disorders. Nature, 444(7121), 860-867.

23- IDF (International Diabetes Federation). (2021). IDF Diabetes Atlas. Diabetes Research and Clinical Practice, 138, 271–281.

24- IDF Diabetes Atlas. (n.d.). Copyright © IDF Diabetes Atlas 2024.

25- Khan, M. A., et al. (2020). Socioeconomic impact of diabetes. The Lancet Diabetes & Endocrinology, 7(9), 673-679.

26- Lowell, B. B., & Shulman, G. I. (2019). Mitochondrial dysfunction and type 2 diabetes. Science, 307(5708), 384–387.

27- Maechler, P., & Wollheim, C. B. (2020). Mitochondrial signaling in diabetes. Endocrine Reviews, 23(5), 252-271.

28- Nicholls, D. G. (2018). Mitochondria and calcium signaling. Cell Calcium, 44(3), 259-263.

29- Odegaard, J. I., & Chawla, A. (2020). Mechanisms of inflammation in T2D. Diabetes, 61(6), 1376–1386.

30- Pankow, J. S., et al. (2018). Cytokine levels and T2D. Diabetologia, 45(4), 485-491.

31- Petersen, K. F., & Shulman, G. I. (2018). Pathogenesis of insulin resistance. Annual Review of Medicine, 57, 233–243.

32- Pickup, J. C. (2019). Inflammation and T2D. Diabetes Technology & Therapeutics, 10(9), 497–506.

33- Saeedi, P., et al. (2019). Global and regional diabetes prevalence. Diabetes Research and Clinical Practice, 157, 107843.

34- Taylor, R. (2020). Insulin resistance and T2D progression. Diabetologia, 50(1), 198-208.

35- Type 2 diabetes. (2024, October 11). Cleveland Clinic.

36- Vlassara, H., & Uribarri, J. (2013). Advanced glycation end products (AGE) and diabetes: Cause, effect, or both? Current Diabetes Reports, 14(1).

37- Vlassara, H., et al. (2019). Advanced glycation and diabetes. Diabetes & Metabolism, 31(4), 139-144.

38- Wandile, P. M. (2023). Diabetic nephropathy and management. SCIRP.

39- Wang, C., et al. (2020). Role of oxidative stress in T2D. Antioxidants & Redox Signaling, 26(4), 1405-1420.

40- Yamagishi, S., & Matsui, T. (2020). Role of advanced glycation end-products in diabetes. Clinical Science, 116(8), 57–67.

41- Zheng, Y., et al. (2018). Global diabetes statistics. Diabetes Spectrum, 30(3), 204–212.